SEC Tracker
Get the app

Synergy CHC SNYRQ

Synergy CHC Q1 FY20: revenue $6.1M, down 35%; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Synergy CHC reported for Q1 FY20, the quarter ended Mar 31, 2020, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$6.1M−35% from $9.5M in Q1 FY1910-Q income statement, on EDGAR
  2. Net income$262K−82% from $1.5M in Q1 FY1910-Q income statement, on EDGAR
  3. Diluted EPS$0.00−100% from $0.02 in Q1 FY1910-Q income statement, on EDGAR
  4. Cash and cash equivalents$315K−54% from $689K in Q1 FY1910-Q balance sheet, on EDGAR
  5. Cash from operations−$1.3M−260% from $814K in Q1 FY1910-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Synergy CHC files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. Cellectar Biosciences CLRB public float $13M, Jun 30, 2025
  2. Earth Science Tech ETST public float $14M, Mar 31, 2026
  3. GeoVax Labs GOVX public float $14M, Jun 30, 2025
  4. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old
  5. Cypherpunk Technologies CYPH public float $12M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.